Structural basis for the inhibition of RecBCD by Gam and its synergistic antibacterial effect with quinolones

Structural basis for the inhibition of RecBCD by Gam and its synergistic antibacterial effect with quinolones

Our previous paper (Wilkinson et al, 2016) used high-resolution cryo-electron microscopy to solve the structure of the Escherichia coli RecBCD complex, which acts in both the repair of double-stranded DNA breaks and the degradation of bacteriophage DNA. To counteract the latter activity, bacteriopha...

Full description

Bibliographic Details
Main Authors:	Martin Wilkinson, Luca A Troman, Wan AK Wan Nur Ismah, Yuriy Chaban, Matthew B Avison, Mark S Dillingham, Dale B Wigley
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2016-12-01
Series:	eLife
Subjects:	DNA repair RecBCD antibacterials
Online Access:	https://elifesciences.org/articles/22963

Similar Items

Mechanism for nuclease regulation in RecBCD
by: Martin Wilkinson, et al.
Published: (2016-09-01)

Structures of RecBCD in complex with phage-encoded inhibitor proteins reveal distinctive strategies for evasion of a bacterial immunity hub
by: Martin Wilkinson, et al.
Published: (2022-12-01)

Synergy between RecBCD subunits is essential for efficient DNA unwinding
by: Rani Zananiri, et al.
Published: (2019-01-01)

Genetic Requirements for Conjugational Recombination in the Presence of λ Gam Protein in Escherichia coli
by: Ivana Ivančić-Baće, et al.
Published: (2002-01-01)

Chromosome Segregation and Cell Division Defects in <i>Escherichia coli</i> Recombination Mutants Exposed to Different DNA-Damaging Treatments
by: Ksenija Zahradka, et al.
Published: (2023-03-01)

Established and Emerging Methods for Protecting Linear DNA in Cell-Free Expression Systems
by: Trevor J. Fochtman, et al.
Published: (2023-03-01)

Auxiliary ATP binding sites support DNA unwinding by RecBCD
by: Rani Zananiri, et al.
Published: (2022-04-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

A homologous DNA recombination pathway alternative to RecFOR and RecBCD induced by gamma irradiation in Salmonella typhimurium
by: Elizabeth Cuétara, et al.

BCD-100 - first russian PD-1 inhibitor
by: S A Tyulyandin, et al.
Published: (2017-09-01)

The RecX protein interacts with the RecA protein and modulates its activity in Herbaspirillum seropedicae
by: C.W. Galvão, et al.
Published: (2012-12-01)

The RecX protein interacts with the RecA protein and modulates its activity in Herbaspirillum seropedicae
by: C.W. Galvão, et al.
Published: (2012-12-01)

Direct observation of end resection by RecBCD during double-stranded DNA break repair in vivo
by: Wiktor, J, et al.
Published: (2017)

Design of High Speed BCD Adder Using CMOS Technology
by: Abdelsalam Al Share, et al.
Published: (2023-01-01)

Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
by: E O Ignatova, et al.
Published: (2016-06-01)

Evaluation of the Role of RecA Protein in Plant Virulence with recA Mutants of Xanthomonas campestris pv. campestris
by: Socorro Martínez, et al.
Published: (1997-09-01)

Biochemical characterization of RecBCD enzyme from an Antarctic Pseudomonas species and identification of its cognate Chi (χ) sequence.
by: Theetha L Pavankumar, et al.
Published: (2018-01-01)

Single-Stranded DNA-Binding Protein and Exogenous RecBCD Inhibitors Enhance Phage-Derived Homologous Recombination in Pseudomonas
by: Jia Yin, et al.
Published: (2019-04-01)

PcrA Dissociates RecA Filaments and the SsbA and RecO Mediators Counterbalance Such Activity
by: Begoña Carrasco, et al.
Published: (2022-02-01)

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Bacteriophage 434 Hex Protein Prevents RecA-Mediated Repressor Autocleavage
by: Paul Shkilnyj, et al.
Published: (2013-01-01)

Division-induced DNA double strand breaks in the chromosome terminus region of Escherichia coli lacking RecBCD DNA repair enzyme.
by: Anurag Kumar Sinha, et al.
Published: (2017-10-01)

Structural and Biochemical Analysis of the Recombination Mediator Protein RecR from <i>Campylobacter jejuni</i>
by: Su-jin Lee, et al.
Published: (2023-08-01)

A new insight into RecA filament regulation by RecX from the analysis of conformation-specific interactions
by: Aleksandr Alekseev, et al.
Published: (2022-06-01)

Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial
by: Sh. Erdes, et al.
Published: (2019-12-01)

Intelligent-BCD: A Novel Knowledge-Transfer Building Change Detection Framework for High-Resolution Remote Sensing Imagery
by: Haiming Zhang, et al.
Published: (2022-01-01)

All three subunits of RecBCD enzyme are essential for DNA repair and low-temperature growth in the Antarctic Pseudomonas syringae Lz4W.
by: Theetha L Pavankumar, et al.
Published: (2010-01-01)

A unified REC market and composite RPO scheme for promotion of renewable energy in India
by: R.M. Shereef, et al.
Published: (2017-07-01)

Bacillus subtilis RarA Acts as a Positive RecA Accessory Protein
by: Hector Romero, et al.
Published: (2020-02-01)

A model for the RecA protein of Mycoplasma synoviae
by: Marbella Maria Fonseca, et al.
Published: (2007-01-01)

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
by: A. V. Samtsov, et al.
Published: (2018-01-01)

Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
by: A. L. Bakulev, et al.
Published: (2019-10-01)

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-07-01)

<i>Bacillus subtilis</i> RadA/Sms-Mediated Nascent Lagging-Strand Unwinding at Stalled or Reversed Forks Is a Two-Step Process: RadA/Sms Assists RecA Nucleation, and RecA Loads RadA/Sms
by: Rubén Torres, et al.
Published: (2023-02-01)

RecQ helicases and genome stability: lessons from model organisms and human disease
by: L Bjergbaek, et al.
Published: (2002-08-01)

Recombination Mediator Proteins: Misnomers That Are Key to Understanding the Genomic Instabilities in Cancer
by: Justin Courcelle, et al.
Published: (2022-02-01)

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis
by: A. L. Bakulev
Published: (2019-02-01)

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-09-01)

Structural basis for DNA 5´-end resection by RecJ
by: Kaiying Cheng, et al.
Published: (2016-04-01)